Data from Codiak’s exoASO™-STAT6 Preclinical Development Program for Treatment of Primary and Metastatic Hepatic Cancers Published in Science Advances; Unprecedented Monotherapy Activity Via Exosome-Based Macrophage Reprogramming In Preclinical Models

On February 18, 2022, Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, announced the online open-access publication of a new manuscript, “Exosome-Mediated Genetic Reprogramming of Tumor-Associated Macrophages by Exoaso-STAT6 Leads to Potent Monotherapy Anti-Tumor Efficacy,” in the American Association for the Advancement of Science’s (AAAS’s) journal, Science Advances. exoASO™-STAT6 is a novel, engineered exosome precision medicine candidate in development for the treatment of macrophage-rich tumors. This new publication details the findings from the preclinical development program and highlights the ability of exoASO-STAT6 to selectively target tumor associated immune-suppressive macrophages (TAMs) and precisely disrupt STAT6 signaling to generate impressive monotherapy anti-tumor activity in cancer models.